RPH en es it fr

RPH Brand names, RPH Analogs

RPH Brand Names Mixture

  • No information avaliable

RPH Chemical_Formula


RPH RX_link


RPH fda sheet

RPH msds (material safety sheet)

RPH Synthesis Reference

No information avaliable

RPH Molecular Weight

192.258 g/mol

RPH Melting Point

246-266 oC

RPH H2O Solubility

1.07E+004 mg/L

RPH State




RPH Dosage Forms

400 mg and 600 mg tablets for oral administration

RPH Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

RPH Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

RPH Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

RPH side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

RPH Patient Information

RPH Organisms Affected

Humans and other mammals